Ionis completes subject enrolment in Alexander disease treatment trial
Ionis Pharmaceuticals has announced the completion of subject enrolment in the Phase I-III clinical trial evaluating Zilganersen (ION373) in individuals…
Ionis Pharmaceuticals has announced the completion of subject enrolment in the Phase I-III clinical trial evaluating Zilganersen (ION373) in individuals…
The Ivy Brain Tumor Center at Barrow Neurological Institute in the US has announced the dosing of the first subject…
SPR Therapeutics has reported positive long-term data for its SPRINT PNS pain management system, as well as primary endpoint results…
The US Food and Drug Administration (FDA) has approved Artelo Biosciences’ investigational new drug (IND) application, greenlighting a Phase I…
According to Parkinson’s UK, one in 37 people in the UK will be diagnosed with Parkinson’s disease (PD) in their…
Eisai is starting recruitment for aPhase I trial evaluating E2086, a novel selective orexin-2 receptor, in patients with narcolepsy type 1.…
At the 10th Congress of the European Academy of Neurology (EAN) 2024, two posters were presented on the real-world clinical…
IntelGenx has announced preliminary efficacy results from its Phase IIa BUENA clinical trial, evaluating Montelukast (MTK) in adults with mild…
On 29 June, at the 10th Congress of the European Academy of Neurology (EAN), the early treatment of migraine to…
INmune Bio’s AD02 trial has bounced back from a previous US Food and Drug Administration (FDA) clinical hold, with the…